[go: up one dir, main page]

CL2018002698A1 - Tratamiento de enfermedades inflamatorias con inhibidores de actividad c5a - Google Patents

Tratamiento de enfermedades inflamatorias con inhibidores de actividad c5a

Info

Publication number
CL2018002698A1
CL2018002698A1 CL2018002698A CL2018002698A CL2018002698A1 CL 2018002698 A1 CL2018002698 A1 CL 2018002698A1 CL 2018002698 A CL2018002698 A CL 2018002698A CL 2018002698 A CL2018002698 A CL 2018002698A CL 2018002698 A1 CL2018002698 A1 CL 2018002698A1
Authority
CL
Chile
Prior art keywords
treatment
inflammatory diseases
activity inhibitors
activity
inhibitors
Prior art date
Application number
CL2018002698A
Other languages
English (en)
Inventor
Renfeng Guo
Niels R Riedemann
Original Assignee
Inflarx Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Inflarx Gmbh filed Critical Inflarx Gmbh
Publication of CL2018002698A1 publication Critical patent/CL2018002698A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6807—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug or compound being a sugar, nucleoside, nucleotide, nucleic acid, e.g. RNA antisense
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/711—Natural deoxyribonucleic acids, i.e. containing only 2'-deoxyriboses attached to adenine, guanine, cytosine or thymine and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Endocrinology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

LA PRESENTE INVENCIÓN SE REFIERE A INHIBIDORES DE LA ACTIVIDAD DE C5A Y SU USO EN EL TRATAMIENTO DE ENFERMEDADES INFLAMATORIAS, NEUTRÓFILAS, CUTÁNEAS EN UN SUJETO.
CL2018002698A 2017-04-03 2018-09-24 Tratamiento de enfermedades inflamatorias con inhibidores de actividad c5a CL2018002698A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP17164573 2017-04-03
EP17177657 2017-06-23
EP17189938 2017-09-07

Publications (1)

Publication Number Publication Date
CL2018002698A1 true CL2018002698A1 (es) 2018-12-07

Family

ID=61024731

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2018002698A CL2018002698A1 (es) 2017-04-03 2018-09-24 Tratamiento de enfermedades inflamatorias con inhibidores de actividad c5a

Country Status (17)

Country Link
US (1) US11273225B2 (es)
EP (3) EP4272821A3 (es)
JP (2) JP7486415B2 (es)
KR (1) KR20190138806A (es)
CN (1) CN111108118A (es)
AU (1) AU2018249310A1 (es)
CA (1) CA3058023A1 (es)
CL (1) CL2018002698A1 (es)
DK (1) DK3411400T3 (es)
ES (1) ES2893769T3 (es)
IL (1) IL261809B2 (es)
MX (1) MX2019011825A (es)
PL (1) PL3411400T3 (es)
SG (1) SG11201807998WA (es)
TW (2) TWI826364B (es)
WO (1) WO2018184739A1 (es)
ZA (1) ZA201906485B (es)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3056568B1 (en) 2006-03-31 2021-09-15 Chugai Seiyaku Kabushiki Kaisha Methods for controlling blood pharmacokinetics of antibodies
CN101874042B9 (zh) 2007-09-26 2019-01-01 中外制药株式会社 利用cdr的氨基酸取代来改变抗体等电点的方法
CA2721052C (en) 2008-04-11 2023-02-21 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule capable of binding to two or more antigen molecules repeatedly
CN103328632A (zh) 2010-11-30 2013-09-25 中外制药株式会社 与多分子的抗原重复结合的抗原结合分子
AR103162A1 (es) 2014-12-19 2017-04-19 Chugai Pharmaceutical Co Ltd Anticuerpos anti-c5 y métodos para su uso
IL278014B2 (en) 2014-12-19 2023-10-01 Chugai Pharmaceutical Co Ltd Anti-myostatin antibodies, polypeptides containing variable FC regions and methods of use
CN109689099B (zh) 2016-08-05 2023-02-28 中外制药株式会社 用于预防或治疗il-8相关疾病的组合物
KR20190138806A (ko) 2017-04-03 2019-12-16 인플라알엑스 게엠베하 C5a 활성 억제제에 의한 염증 질병의 치료
US10376595B2 (en) 2017-04-03 2019-08-13 Inflarx Gmbh Treatment of inflammatory diseases with inhibitors of C5a activity
CA3066689C (en) * 2017-06-23 2024-01-16 Inflarx Gmbh Treatment of inflammatory diseases with inhibitors of c5a activity
HUE069633T2 (hu) 2018-11-30 2025-04-28 Chemocentryx Inc Kapszulás készítmények
TW202100179A (zh) * 2019-03-08 2021-01-01 美商Ｒａ製藥公司 補體活性之調節劑
CA3129019A1 (en) 2019-03-11 2020-09-17 Yong Li Fused piperidinyl bicyclic and related compounds as modulators of c5a receptor
SG11202109837SA (en) * 2019-04-24 2021-10-28 Ra Pharmaceuticals Inc Compositions and methods for modulating complement activity
TWI869528B (zh) 2020-01-13 2025-01-11 美商威特拉公司 C5ar1抗體分子及其用途
CN116615454A (zh) * 2020-08-12 2023-08-18 先天制药公司 采用艾朵利单抗的皮下抗c5ar拮抗剂治疗方案
CN116529241A (zh) * 2020-10-28 2023-08-01 坎莫森特里克斯公司 治疗化脓性汗腺炎的方法
CA3192880A1 (en) * 2020-10-28 2022-05-05 Chemocentryx, Inc. Methods of treating hidradenitis suppurativa
TW202246331A (zh) 2021-01-13 2022-12-01 美商威特拉公司 人源化補體５ａ受體１抗體及其使用方法
CN116036233A (zh) * 2023-01-10 2023-05-02 中山大学附属第八医院（深圳福田） 小分子化合物pmx 53在制备抑制血管钙化和血管纤维化药物中的应用
US12180274B2 (en) 2023-05-26 2024-12-31 Inflarx Gmbh Treatment of pneumonia and ARDS with inhibitors of C5a and IL-6 activity

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4704355A (en) 1985-03-27 1987-11-03 New Horizons Diagnostics Corporation Assay utilizing ATP encapsulated within liposome particles
AU6501390A (en) 1989-09-21 1991-04-18 Synergen, Inc. Method for transporting compositions across the blood brain barrier
EP1690935A3 (en) 1990-01-12 2008-07-30 Abgenix, Inc. Generation of xenogeneic antibodies
US6074642A (en) 1994-05-02 2000-06-13 Alexion Pharmaceuticals, Inc. Use of antibodies specific to human complement component C5 for the treatment of glomerulonephritis
AUPO755097A0 (en) 1997-06-25 1997-07-17 University Of Queensland, The Receptor agonist and antagonist
US20030133939A1 (en) 2001-01-17 2003-07-17 Genecraft, Inc. Binding domain-immunoglobulin fusion proteins
US7754208B2 (en) 2001-01-17 2010-07-13 Trubion Pharmaceuticals, Inc. Binding domain-immunoglobulin fusion proteins
AUPR833401A0 (en) 2001-10-17 2001-11-08 University Of Queensland, The G protein-coupled receptor antagonists
WO2003074679A2 (en) 2002-03-01 2003-09-12 Xencor Antibody optimization
ES2674129T3 (es) 2004-02-12 2018-06-27 Archemix Llc Agentes terapéuticos de base aptámeros útiles en el tratamiento de trastornos relacionados con complemento
CN101553244B (zh) 2006-07-21 2013-01-02 普罗米克斯有限公司 内膜增生和相关病状的治疗
RU2009110154A (ru) * 2006-08-22 2010-09-27 Джи2 ИНФЛЕММЕЙШН ПТИ ЛТД (AU) АНТИТЕЛА ПРОТИВ C5aR С УЛУЧШЕННЫМИ СВОЙСТВАМИ
GB0617734D0 (en) 2006-09-08 2006-10-18 Evolutec Ltd Method of treating peripheral nerve disorders
MA32975B1 (fr) 2008-12-22 2012-01-02 Chemocentryx Inc Antagonistes de c5ar
US9290736B2 (en) * 2009-11-04 2016-03-22 Case Western Reserve University Compositions and methods of treating T cell mediated disorder
EP2327725A1 (en) * 2009-11-26 2011-06-01 InflaRx GmbH Anti-C5a binding moieties with high blocking activity
SI2585064T1 (sl) 2010-06-24 2017-08-31 Chemocentryx, Inc. Antagonisti C5AR
WO2014160129A2 (en) 2013-03-14 2014-10-02 Alnylam Pharmaceuticals, Inc. Complement component c5 irna compositions and methods of use thereof
JP6718379B2 (ja) 2014-03-20 2020-07-08 インフラルクス ゲーエムベーハー ウイルス性肺炎治療のためのＣ５ａの阻害剤
EP3194596A1 (en) 2014-09-16 2017-07-26 Alnylam Pharmaceuticals, Inc. Complement component c5 irna compositions and methods of use thereof
WO2016061066A1 (en) 2014-10-15 2016-04-21 Alexion Pharmaceuticals, Inc. Methods of replicating a large scale eculizumab production cell culture
FR3030515B1 (fr) * 2014-12-23 2017-01-20 Galderma Res & Dev Nouveaux composes antagonistes des recepteurs cxcr1 et cxcr2 aux chimiokines, et leur utilisation dans le traitement de pathologies mediees par des chimiokines
US20180142010A1 (en) 2015-06-26 2018-05-24 Alexion Pharmaceuticals, Inc. Method for treating a patient in compliance with vaccination with eculizumab or an eculizumab variant
MX384752B (es) 2016-04-04 2025-03-14 Chemocentryx Inc ANTAGONISTAS SOLUBLES DE RECEPTOR DE C5a (C5aR).
US10376595B2 (en) 2017-04-03 2019-08-13 Inflarx Gmbh Treatment of inflammatory diseases with inhibitors of C5a activity
KR20190138806A (ko) 2017-04-03 2019-12-16 인플라알엑스 게엠베하 C5a 활성 억제제에 의한 염증 질병의 치료
CA3129019A1 (en) 2019-03-11 2020-09-17 Yong Li Fused piperidinyl bicyclic and related compounds as modulators of c5a receptor

Also Published As

Publication number Publication date
SG11201807998WA (en) 2018-12-28
TW202348249A (zh) 2023-12-16
EP4272821A3 (en) 2024-01-03
MX2019011825A (es) 2020-12-11
DK3411400T3 (da) 2021-10-11
IL261809B1 (en) 2023-12-01
CA3058023A1 (en) 2018-10-11
ZA201906485B (en) 2021-08-25
WO2018184739A1 (en) 2018-10-11
EP3411400A1 (en) 2018-12-12
EP4272821A2 (en) 2023-11-08
IL261809B2 (en) 2024-04-01
US20180282425A1 (en) 2018-10-04
EP3978523A1 (en) 2022-04-06
JP2020515643A (ja) 2020-05-28
TW201836641A (zh) 2018-10-16
JP7486415B2 (ja) 2024-05-17
US11273225B2 (en) 2022-03-15
ES2893769T3 (es) 2022-02-10
KR20190138806A (ko) 2019-12-16
AU2018249310A1 (en) 2019-10-17
IL261809A (en) 2018-11-29
EP3411400B1 (en) 2021-09-22
PL3411400T3 (pl) 2021-12-20
TWI826364B (zh) 2023-12-21
CN111108118A (zh) 2020-05-05
JP2022176946A (ja) 2022-11-30

Similar Documents

Publication Publication Date Title
CL2018002698A1 (es) Tratamiento de enfermedades inflamatorias con inhibidores de actividad c5a
IL272410A (en) Cytokine conjugates for the treatment of autoimmune diseases
CL2019001874A1 (es) Inhibidores de tgfß1 isoforma-específicos contexto-permisivos y uso de los mismos.
CY1122344T1 (el) Blautia stercosis και wexlerae για χρηση στην θεραπευτικη αγωγη φλεγμονωδων και αυτοανοσων νοσων
CY1122184T1 (el) Συνθεσεις περιλαμβανουσες βακτηριακα στελεχη
EP3596163A4 (en) CARBON AND ELASTOMER INTEGRATION
MX378686B (es) Composiciones que comprenden cepas bacterianas.
MX389707B (es) Neurotoxinas quimericas.
BR112018009706A2 (pt) composições compreendendo cepas bacterianas
BR112018009213A2 (pt) composições compreendendo cepas bacterianas
BR112017025003A2 (pt) composições compreendendo cepas bacterianas
ECSP17018120A (es) Triazolopirazinonas como inhibidores de pde1
EP3781188A4 (en) ADOPTIVE CELL THERAPY
TR201810635T4 (tr) Anti-jagged1 antikorları ve kullanım yöntemleri.
DOP2017000254A (es) Imidazopirazinonas como inhibidores de pde1
EP3635295C0 (de) Korpusmöbel
MX2018005987A (es) Compuestos heterociclicos para el tratamiento de enfermedades.
DOP2016000263A (es) Quinazolin-thf-aminas halogenadas como inhibidores de pde1
ECSP16071574A (es) Hexahidrofuropirroles como inhibidores de pde1
PL3441639T3 (pl) Zespół tłumika i przeznaczony do niego tłumik
IL271703B (en) Use of macroazapyridinophanes metal complexes in the treatment of diseases
UA39584S (uk) Сережки
AU201715200S (en) Mirror
EA201990509A1 (ru) Применения ингибитора лизилоксидазаподобного белка 2
UA37010S (uk) Стілець